The General Assembly of the Spanish Association of Orphan and Ultra-Orphan Drug Laboratories (AELMHU), comprising its 29 member companies, has elected the Association’s new Board of Directors for the 2026–2028 term.

Beatriz Perales (Sobi) will continue as president of AELMHU for the next two years. Iván Silva (Kyowa Kirin), José Luis Moreno (Ultragenyx), Sergio Bullón (Alnylam), María Fernández (Amgen), Iria Nieto (PTC Therapeutics), and Angelino Ruiz (UCB) round out the new Board of Directors.